BR112022024071A2 - Compostos moduladores de tlr2, composições farmacêuticas e usos dos mesmos - Google Patents

Compostos moduladores de tlr2, composições farmacêuticas e usos dos mesmos

Info

Publication number
BR112022024071A2
BR112022024071A2 BR112022024071A BR112022024071A BR112022024071A2 BR 112022024071 A2 BR112022024071 A2 BR 112022024071A2 BR 112022024071 A BR112022024071 A BR 112022024071A BR 112022024071 A BR112022024071 A BR 112022024071A BR 112022024071 A2 BR112022024071 A2 BR 112022024071A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
compounds
tlr2
modulator compounds
tlr2 modulator
Prior art date
Application number
BR112022024071A
Other languages
English (en)
Inventor
J Oalmann Christopher
S Yamashita Dennis
J Stern Patrick
Original Assignee
Axial Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axial Therapeutics Inc filed Critical Axial Therapeutics Inc
Publication of BR112022024071A2 publication Critical patent/BR112022024071A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

A presente invenção refere-se a compostos que modulam a atividade de proteínas receptoras do tipo Toll (TLR), incluindo agonistas ou ativadores, agonistas parciais e antagonistas. De particular interesse de compostos que modulam a atividade de TLR2, bem como métodos de uso de tais compostos para tratar câncer e outros distúrbios associados a uma via de TLR2.
BR112022024071A 2020-05-27 2021-05-26 Compostos moduladores de tlr2, composições farmacêuticas e usos dos mesmos BR112022024071A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063030370P 2020-05-27 2020-05-27
PCT/US2021/034346 WO2021242923A1 (en) 2020-05-27 2021-05-26 Tlr2 modulator compounds, pharmaceutical compositions and uses thereof

Publications (1)

Publication Number Publication Date
BR112022024071A2 true BR112022024071A2 (pt) 2022-12-20

Family

ID=78722874

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022024071A BR112022024071A2 (pt) 2020-05-27 2021-05-26 Compostos moduladores de tlr2, composições farmacêuticas e usos dos mesmos

Country Status (9)

Country Link
US (1) US11951094B2 (pt)
EP (1) EP4171547A1 (pt)
JP (1) JP2023527792A (pt)
KR (1) KR20230017796A (pt)
CN (1) CN115666553A (pt)
AU (1) AU2021280287A1 (pt)
BR (1) BR112022024071A2 (pt)
CA (1) CA3177546A1 (pt)
WO (1) WO2021242923A1 (pt)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200781D0 (en) 1992-01-15 1992-03-11 Merck Sharp & Dohme Therapeutic agents
FR2819517B1 (fr) 2000-10-03 2003-03-21 Atofina Composition comprenant un nitroxyde, un promoteur et eventuellement un initiateur de radicaux libres
US7226964B2 (en) 2003-04-03 2007-06-05 Arkema France Composition comprising a nitroxide, a promoter and optionally a free-radical initiator
CA2535802A1 (en) 2003-08-21 2005-03-03 Griffith University Novel sulfenamides
EP1664071A1 (en) 2003-08-21 2006-06-07 Griffith University Novel sulfenamide oxides
US7550487B2 (en) * 2004-03-26 2009-06-23 Hoffmann-La Roche Inc. Pyrrolidine-3,4-dicarboxamide derivatives
JP5461009B2 (ja) 2005-06-08 2014-04-02 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 非ペプチド及びペプチドｂｄｎｆニューロトロフィン類似体を用いた神経細胞生存促進法
WO2009022171A1 (en) 2007-08-13 2009-02-19 Astrazeneca Ab Pyridinyiioxy pyridines as alk5 inhibitors
TWI461411B (zh) 2007-08-17 2014-11-21 Du Pont 製備５－鹵烷基－４，５－二氫異唑衍生物之方法
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
JP6460382B2 (ja) 2014-11-28 2019-01-30 株式会社豊田自動織機 飽和ヘテロ環含有化合物、並びにこれを用いた二次電池用電極及び二次電池、結着剤、蛍光物質
EP3322420B1 (en) 2015-07-13 2021-12-29 Merck Sharp & Dohme Corp. Bicyclic heterocycles as inhibitors of cholesterol ester transfer protein
US11040959B2 (en) * 2016-06-29 2021-06-22 The Board Of Regents Of The University Of Texas System Diprovocims: a new and potent class of TLR agonists
WO2018107112A1 (en) 2016-12-09 2018-06-14 University Of Iowa Research Foundation Quinolone-based compounds with anticancer activity
CN107093096B (zh) 2016-12-15 2022-03-25 口碑(上海)信息技术有限公司 一种业务量预测方法及装置
CN106892904A (zh) 2017-03-10 2017-06-27 深圳无微华斯生物科技有限公司 吡咯烷‑2,5‑二酮衍生物的制备方法
AU2018392805A1 (en) 2017-12-22 2020-05-07 Dana-Farber Cancer Institute, Inc. NEK inhibitors and methods of use
KR20210005569A (ko) 2018-04-23 2021-01-14 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 Rsv에 대한 활성을 갖는 헤테로방향족 화합물
WO2020023872A1 (en) 2018-07-27 2020-01-30 Children's Medical Center Corporation Use of toll-like receptor 2 (tlr-2) agonist for modulating human immune response
CN113164445A (zh) * 2018-08-02 2021-07-23 得克萨斯系统大学评议会 Tlr1/2激动剂地普罗考姆的佐剂作用协同增效检查点抑制性抗体以消除疾病
WO2023091747A1 (en) * 2021-11-22 2023-05-25 Axial Therapeutics, Inc. Modulator compounds, pharmaceutical compositions and uses thereof

Also Published As

Publication number Publication date
CN115666553A (zh) 2023-01-31
WO2021242923A1 (en) 2021-12-02
AU2021280287A1 (en) 2023-01-05
EP4171547A1 (en) 2023-05-03
US20230051773A1 (en) 2023-02-16
CA3177546A1 (en) 2021-12-02
KR20230017796A (ko) 2023-02-06
JP2023527792A (ja) 2023-06-30
US11951094B2 (en) 2024-04-09

Similar Documents

Publication Publication Date Title
CL2022000603A1 (es) Inhibidores prmt5 cooperativos de mta
CL2020001133A1 (es) Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2 y métodos de uso de los mismos. (divisional solicitud 201901664)
CL2019002671A1 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1.
BR112016025423A2 (pt) compostos e composições como agonistas de receptores do tipo toll 7
BRPI0909037B8 (pt) compostos moduladores da atividade de tlr, e composição farmacêutica
BR112021021703A2 (pt) Cicloalquilas substituídas como moduladores da via de estresse integrada
BR112014030386A8 (pt) Compostos e composições para modular a atividade de egfr
BR112021005769A2 (pt) proteínas de ligação a dll3 e métodos de uso
BR112015030595A2 (pt) moduladores de receptor de estrogênio de azetidina e usos dos mesmos
BR112018067679A2 (pt) células que expressam múltiplas moléculas do receptor de antígeno quimérico (car) e seu uso
BR112018009798A2 (pt) inibidores de bromodomínio bivalentes e usos dos mesmos
BR112016025048A2 (pt) compostos e composições como agonistas do receptor tipo toll7
BR112017020445A2 (pt) polipeptídeo de fusão, molécula de ácido nucleico, célula hospedeira, método de produção de um polipeptídeo de fusão, uso do polipeptídeo de fusão, método para ativar as vias de sinalização, método para coestimular células, método para induzir a proliferação de linfócitos e método para direcionar o agrupamento de cd137
ECSP15007420A (es) Métodos y composiciones para determinar la resistencia a la terapia con receptor de andrógeno
BR112012004696A2 (pt) compostos e composições como moduladores da atividade de tlr
EA201790896A1 (ru) Пролекарства фенольных агонистов trpv1
BR112022001324A2 (pt) Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo
BR112016006994A8 (pt) inibidores de erk, seus usos e composições farmacêuticas os compreendendo
BR112019001253A2 (pt) composto, composição farmacêutica, e, métodos de tratamento de câncer ou de atrofia muscular e de doença de parkinson.
BR112021025132A2 (pt) Carbamatos de piridina e seu uso como moduladores do receptor glun2b
BR112017023780A2 (pt) sulfonas tricíclicas como moduladores de rorgama
PA8715601A1 (es) Modulacion de la formacion de huesos
BR112016025450A2 (pt) moduladores de canais de íons e usos dos mesmos
BR112022005711A2 (pt) Métodos e composições para tratar uma doença ou transtorno
BR112022021690A2 (pt) Anticorpos de cadeia pesada multispecíficos com regiões constantes de cadeia pesada modificadas